Skip to main
LXEO
LXEO logo

LXEO Stock Forecast & Price Target

LXEO Analyst Ratings

Based on 1 analyst ratings
Buy
Strong Buy 0%
Buy 100%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lexeo Therapeutics Inc's positive outlook is supported by strategic adjustments in operating expenses, reflecting a commitment to align with the company’s growing R&D and general administrative expenses. The increased probability of success for LX2006, from 30% to 40%, is attributed to favorable interim data that aligns with pivotal trial designs, enhancing the program's attractiveness as it targets high unmet medical needs. Significant clinical advancements, such as the observed improvements in cardiac biomarkers and gene expression post-treatment, underscore the potential for meaningful therapeutic outcomes, further solidifying positive investor sentiment.

Bears say

The financial outlook for Lexeo Therapeutics Inc appears negative due to the potential for unmet expectations in clinical trial outcomes, which may lead to downward revisions of future price forecasts. Projected net losses are concerning, with a projected loss of $3.22 per share for the full year 2024, indicating ongoing financial challenges as the company continues to invest in its technology. Additionally, uncertainties surrounding manufacturing capacity and evolving regulatory guidance related to trial design may further constrain the company's ability to meet projections and bring products to market, exacerbating the stance on its financial viability.

LXEO has been analyzed by 1 analysts, with a consensus rating of Buy. 0% of analysts recommend a Strong Buy, 100% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lexeo Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lexeo Therapeutics Inc (LXEO) Forecast

Analysts have given LXEO a Buy based on their latest research and market trends.

According to 1 analysts, LXEO has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lexeo Therapeutics Inc (LXEO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.